Improving Efficiency in Stroke Prevention

Published: 18 February 2021
Likes: 16
Average (rating)
No ratings
Your rating

Overview

LAA closure (LAAC) is a proven alternative to oral anticoagulation for preventing stroke in patients with non-valvular AF.

Please join this webinar at 6pm CEST / 5pm BST on LAAC Patient Management in the COVID-19 Era to reinforce the importance to treat LAA closure patients, overcome barriers during a pandemic and optimizing an elective procedure with the new LAA closure device WATCHMAN FLX.

 

 

 

Learning Objectives

  • Discuss the emerging evidence for the LAA closure therapy in the era of NOACs.
  • Share experience about the management of elective procedures during the pandemic to offer treatment for patients at high risk for stroke.
  • Learn how new imaging modalities (ICE, mini-micro TEE, CT) and workstreams could reduce the need for General Anesthesia, streamlining the LAAC procedure and the patient follow-up.
  • Learn about the latest LAAC clinical data and the proven safety profile of WATCHMAN FLX.
  • Understand how the new implantation technique of WATCHMAN FLX can optimize procedural results.

Audience

  • Interventional Cardiologists
  • Electrophysiologists

Agenda

Rationale for an alternative to DOAC in stroke prevention – J. Camm

- Limitations of lifelong DOAC therapy
- High bleeding risk and special subgroups
- PRAGUE-17, OPTION, CHAMPION-AF

Case presentation – FLX with early discharge – D. Hildick-Smith

- Clinical history
- CT scan – anatomic considerations

Current state of LAAC with a new generation device – T. Betts

- From EWOLUTION to NCDR and PINNACLE FLX

Case conclusion – D. Hildick-Smith

- Implantation technique
- Imaging guidance selection / anesthesia (GA vs. sedation)
- Post-procedure antithrombotic therapy

Panel Discussion and Conclusion

Boston Scientific